Literature DB >> 9796698

Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression.

S Bates1, K M Ryan, A C Phillips, K H Vousden.   

Abstract

p21Waf1/Cip1 is a major transcriptional target of p53 and has been shown to be one of the principal mediators of the p53 induced G1 cell cycle arrest. We show that in addition to the G1 block, p21Waf1/Cip1 can also contribute to a delay in G2 and expression of p21Waf1/Cip1 gives rise to cell cycle profiles essentially indistinguishable from those obtained following p53 expression. Arrest of cells in G2 likely reflects an inability to induce cyclin B1/cdc2 kinase activity in the presence of p21Waf1/Cip1, although the inefficient association of p21Waf1/Cip1 and cyclin B1 suggests that the mechanism of inhibition is indirect. Cells released from an S-phase block were not retarded in their ability to progress through S-phase by the presence of p21Waf1/Cip1, despite efficient inhibition of cyclin E, A and B1 dependent kinase activity, suggesting that p21Waf1/Cip1 is inefficient at inhibiting replicative DNA synthesis in vivo. Interestingly, significant numbers of cells released from the p21Waf1/Cip1 activated G2 block undergo endoreduplication, passing through another S-phase before undergoing mitosis. This supports a function of the mitotic kinases in both entry into mitosis, and also in preventing re-replication of DNA following S-phase and suggests a role for p21Waf1/Cip1 in coupling DNA synthesis and mitosis. Unlike p53, which induces apoptosis in these cells, extended expression of p21Waf1/Cip1 resulted in the expression of a senescent-like phenotype in these p53 null, pRB null tumor cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796698     DOI: 10.1038/sj.onc.1202104

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  47 in total

1.  A quantitative analysis of the kinetics of the G(2) DNA damage checkpoint system.

Authors:  B D Aguda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells.

Authors:  D Chattopadhyay; M K Ghosh; A Mal; M L Harter
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 3.  Control of the G2/M transition.

Authors:  George R Stark; William R Taylor
Journal:  Mol Biotechnol       Date:  2006-03       Impact factor: 2.695

Review 4.  p53 and regulation of bioactive sphingolipids.

Authors:  Linda A Heffernan-Stroud; Lina M Obeid
Journal:  Adv Enzyme Regul       Date:  2010-10-28

Review 5.  Switching the cell cycle. Kip-related proteins in plant cell cycle control.

Authors:  Aurine Verkest; Christina Weinl; Dirk Inzé; Lieven De Veylder; Arp Schnittger
Journal:  Plant Physiol       Date:  2005-11       Impact factor: 8.340

6.  Replication-dependent destruction of Cdt1 limits DNA replication to a single round per cell cycle in Xenopus egg extracts.

Authors:  Emily E Arias; Johannes C Walter
Journal:  Genes Dev       Date:  2004-12-14       Impact factor: 11.361

7.  APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase.

Authors:  Virginia Amador; Sheng Ge; Patricia G Santamaría; Daniele Guardavaccaro; Michele Pagano
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

8.  Xaf1 can cooperate with TNFalpha in the induction of apoptosis, independently of interaction with XIAP.

Authors:  Yan Xia; Rachel Novak; Jennifer Lewis; Colin S Duckett; Andrew C Phillips
Journal:  Mol Cell Biochem       Date:  2006-01-24       Impact factor: 3.396

9.  The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells.

Authors:  Tze-Chen Hsieh; Frank Traganos; Zbigniew Darzynkiewicz; Joseph M Wu
Journal:  Int J Oncol       Date:  2007-12       Impact factor: 5.650

Review 10.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.